Teva Pays $235M to GSK after Coreg Patent Trial

Jun 22, 2017

Reuters

A jury in Wilmington, Delaware, ordered Teva Pharmaceutical Industries to pay GlaxoSmithKline more than $235 million for violating a patent of its its blood pressure medicine Coreg, according to a Reuters article.

The jury ruled that Teva infringed the patent with its sales of a generic version of GSK's Coreg with a label saying it could treat chronic heart failure, the story said.

The jury rejected Teva's argument that the patent was invalid.

Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments